 WALTHAM, Mass., Aug. 23, 2021 GLOBE NEWSWIRE -- Morphic Therapeutic Nasdaq: MORF, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Nisha Nanda, Ph.D., to its Board of Directors. Dr. Nanda currently serves as the chief development officer for Loxo Oncology at Lilly. 